ScreenerHero

SYRS Syros Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · syros.com
0.0004USD-96.67%Mkt Cap: 10732 $P/E: —

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap10.73K USD
Enterprise Value1.96M USD
Revenue (TTM)386.00K USD
Gross Profit-88.25M USD
Net Income (TTM)-164.57M USD
Revenue/Share0.01 USD
Last Price0.0004 USD
Fiscal Year EndDec 2023
MR QuarterSep 2024
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA-0.02
EV/Revenue5.08
P/S0.03
P/B-0.00
EPS (TTM)-6.14
EPS (Forward)-2.61
52W Range
0.00012% of range0.0200
52W High0.0200 USD
52W Low0.0001 USD
Profitability
Gross Margin0.00%
Oper. Margin-28891.71%
EBITDA Margin0.00%
Profit Margin-1656.34%
ROE-987.72%
ROA-97.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-109.71M USD
CapEx (TTM)272.00K USD
FCF Margin-15011.01%
FCF Yield-539904.03%
Net Debt1.95M USD
Net Debt/EBITDA-0.02
Balance Sheet
Debt/Equity3.73
Current Ratio2.25
Quick Ratio2.05
Book Value/Sh-0.41 USD
Cash/Share2.17 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateSep 19, 2022
Analyst Consensus
Rating—
Target (Mean)8.750 USD
Upside (mean)+2187400.1%
Target Range4.000 USD – 20.00 USD
4.000+2187400.1% to mean20.00
# Analysts4
Ownership
Shares Out.26.83M
Float26.83M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio0.1d
Short % Float17.01%
Short % Out.15.63%
Shares Short4.19M
Short (prev mo.)913.09K
Technical
SMA 500.0005 (-24.8%)
SMA 2000.0003 (+21.0%)
Beta1.69
S&P 52W Chg16.45%
Avg Vol (30d)11.29K
Avg Vol (10d)24.54K
Technical Indicators
RSI (14)48.4
MACD0.0008
MACD Signal0.0004
MACD Hist.+0.0004
BB Upper0.0061 USD
BB Middle0.0009 USD
BB Lower-0.0043 USD
BB Width1176.96%
ATR (14)0.0017 USD
Vol Ratio (20d)0.51x